https://www.selleckchem.com/pr....oducts/pnd-1186-vs-4
40; P = 0.001). This data was confirmed for patients treated with the combination of ICIs plus anti-VEGFR tyrosine kinase inhibitors (RR = 2.50; P = 0.002). In PD-L1 positive tumors, the incidence of CR was 10.0% with ICIs and 4.0% in the SOC arm (RR = 2.49; P 0.0001). ICIs provide higher rates of CR compared to SOC, even higher in patients with PD-L1 positive tumors. ICIs provide higher rates of CR compared to SOC, even higher in patients with PD-L1 positive tumors. Upper tract urothelial carcinoma (UTUC) is relatively ra
Curtir
Comentario
Compartilhar
